Abstract
Twenty-eight patients with inoperable non-small cell carcinoma of the lung were treated with high-dose methotrexate with citrovorum factor rescue. One patient (4%) responded with a partial regression of the tumor. Three patients had severe or life-threatening complications: acute renal failure, acute shortness of breath, and bone marrow suppression, respectively. There is 98% confidence that the true response rate for this therapy is
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1017-1021 |
| Number of pages | 5 |
| Journal | Cancer Treatment Reports |
| Volume | 64 |
| Issue number | 10-11 |
| State | Published - 1980 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung : An Eastern Cooperative Oncology Group Study. / Ettinger, David S; Stanley, K. E.; Nystrom, J. S.
In: Cancer Treatment Reports, Vol. 64, No. 10-11, 1980, p. 1017-1021.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung
T2 - An Eastern Cooperative Oncology Group Study
AU - Ettinger, David S
AU - Stanley, K. E.
AU - Nystrom, J. S.
PY - 1980
Y1 - 1980
N2 - Twenty-eight patients with inoperable non-small cell carcinoma of the lung were treated with high-dose methotrexate with citrovorum factor rescue. One patient (4%) responded with a partial regression of the tumor. Three patients had severe or life-threatening complications: acute renal failure, acute shortness of breath, and bone marrow suppression, respectively. There is 98% confidence that the true response rate for this therapy is
AB - Twenty-eight patients with inoperable non-small cell carcinoma of the lung were treated with high-dose methotrexate with citrovorum factor rescue. One patient (4%) responded with a partial regression of the tumor. Three patients had severe or life-threatening complications: acute renal failure, acute shortness of breath, and bone marrow suppression, respectively. There is 98% confidence that the true response rate for this therapy is
UR - http://www.scopus.com/inward/record.url?scp=0019273060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019273060&partnerID=8YFLogxK
M3 - Article
VL - 64
SP - 1017
EP - 1021
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 10-11
ER -